Vir Biotechnology Share Price (NASDAQ: VIR)

$4.95

▲

-0.09

(-1.79%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Vir Biotechnology Stock chart to analyse performance

Vir Biotechnology stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$4.87
Today's High:$5.08
$4.95
1.72%
Downside
Day's Volatility :4.23%
Upside
2.56%
52 Weeks Low:$4.16
52 Weeks High:$14.45
$4.95
16.06%
Downside
52 Weeks Volatility :71.25%
Upside
65.74%

Vir Biotechnology Stock Returns

Period	Vir Biotechnology Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-2.47%	3.6%	0.0%
6 Months	-37.56%	-7.7%	0.0%
1 Year	-36.44%	-12.6%	0.0%
3 Years	-79.68%	9.5%	-4.7%

Vir Biotechnology Inc Key Stats

Check Vir Biotechnology key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$5.04
Open	$5.02
Today's High	$5.08
Today's Low	$4.865
Market Capitalization	$726.5M
Today's Volume	$1.7M
52 Week High	$14.45
52 Week Low	$4.155
Revenue TTM	$19.0M
EBITDA	$-554.7M
Earnings Per Share (EPS)	$-4.01
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.59%
Return On Equity TTM	-46.22%

Stock Returns calculator for Vir Biotechnology Stock including INR - Dollar returns

The Vir Biotechnology stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Vir Biotechnology investment value today

Current value as on today

₹68,909

Returns

₹31,091

(-31.09%)

Returns from Vir Biotechnology Stock

₹36,375 (-36.38%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Vir Biotechnology Stock

-42%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Vir Biotechnology Stock from India on INDmoney has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Vir Biotechnology Inc

Name
Holdings %
Name
Holdings %
SB INVESTMENT ADVISERS (UK) LTD
12.01%
BlackRock Inc
11.91%
Vanguard Group Inc
9.52%
State Street Corp
4.12%
Dimensional Fund Advisors, Inc.
2.17%
Geode Capital Management, LLC
1.65%

Analyst Recommendation on Vir Biotechnology Stock

Rating

Trend

Buy

69%Buy

30%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Vir Biotechnology(by analysts ranked 0 to 5 stars)

Vir Biotechnology Share Price Target

What analysts predicted

Upside of 261.11%

Target:

$17.88

Current:

$4.95

Vir Biotechnology share price target is $17.88, a slight Upside of 261.11% compared to current price of $4.95 as per analysts' prediction.

Vir Biotechnology Stock Insights

Price Movement
In the last 7 days, VIR stock has moved up by 8.0%
Decreasing Revenue
Revenue is down for the last 3 quarters, 11.27M → 1.21M (in $), with an average decrease of 58.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -120.96M → -110.95M (in $), with an average increase of 9.0% per quarter
VIR vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 110.0%
VIR vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 192.3%
Price to Sales
ForVIR every $1 of sales, investors are willing to pay $35.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Vir Biotechnology Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$711.0K	↓ 18.09%
Net Income	$-174.7M	↑ 50.74%
Net Profit Margin	-24.6K%	↓ 11217.95%

	FY20	Y/Y Change
Revenue	$76.4M	↑ 10640.93%
Net Income	$-298.7M	↑ 70.98%
Net Profit Margin	-391.09%	↑ 24177.55%

	FY21	Y/Y Change
Revenue	$1.1B	↑ 1323.46%
Net Income	$528.6M	↓ 276.98%
Net Profit Margin	48.62%	↑ 439.71%

	FY22	Y/Y Change
Revenue	$1.6B	↑ 45.39%
Net Income	$515.8M	↓ 2.41%
Net Profit Margin	32.64%	↓ 15.98%

	FY23	Y/Y Change
Revenue	$86.2M	↓ 94.55%
Net Income	$-615.1M	↓ 219.24%
Net Profit Margin	-713.69%	↓ 746.33%

	FY24	Y/Y Change
Revenue	$74.2M	↓ 13.9%
Net Income	$-522.0M	↓ 15.14%
Net Profit Margin	-703.4%	↑ 10.29%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$56.4M	↑ 235.83%
Net Income	$-65.3M	↓ 43.71%
Net Profit Margin	-115.79%	↑ 575.06%

	Q2 FY24	Q/Q Change
Revenue	$3.1M	↓ 94.55%
Net Income	$-138.4M	↑ 111.99%
Net Profit Margin	-4.5K%	↓ 4384.31%

	Q3 FY24	Q/Q Change
Revenue	$2.4M	↓ 22.6%
Net Income	$-213.7M	↑ 54.44%
Net Profit Margin	-9.0K%	↓ 4479.61%

	Q4 FY24	Q/Q Change
Revenue	$11.3M	↑ 373.87%
Net Income	$-104.6M	↓ 51.06%
Net Profit Margin	-927.37%	↑ 8052.34%

	Q1 FY25	Q/Q Change
Revenue	$1.8M	↓ 84.09%
Net Income	$-121.0M	↑ 15.66%
Net Profit Margin	-6.7K%	↓ 5815.38%

	Q2 FY25	Q/Q Change
Revenue	$1.2M	↓ 32.33%
Net Income	$-111.0M	↓ 8.27%
Net Profit Margin	-9.1K%	↓ 2397.12%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$711.0K	↓ 100.72%

	FY20	Y/Y Change
Profit	$76.4M	↑ 10640.93%

	FY21	Y/Y Change
Profit	$1.0B	↑ 1237.21%

	FY22	Y/Y Change
Profit	$1.4B	↑ 40.44%

	FY23	Y/Y Change
Profit	$83.4M	↓ 94.18%

	FY24	Y/Y Change
Profit	$73.4M	↓ 12.05%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$51.8M	↑ 350.04%

	Q2 FY24	Q/Q Change
Profit	$-1.2M	↓ 102.39%

	Q3 FY24	Q/Q Change
Profit	$2.3M	↓ 288.36%

	Q4 FY24	Q/Q Change
Profit	$10.6M	↑ 354.68%

	Q1 FY25	Q/Q Change
Profit	$1.8M	↓ 83.07%

	Q2 FY25	Q/Q Change
Profit	$1.2M	↓ 32.94%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-129.6M	↑ 37.77%
Investing Cash Flow	$-256.2M	↑ 323.81%
Financing Cash Flow	$449.2M	↑ 1698.56%

	FY20	Y/Y Change
Operating Cash Flow	$-190.9M	↑ 47.29%
Investing Cash Flow	$-9.9M	↓ 96.15%
Financing Cash Flow	$529.5M	↑ 17.86%

	FY21	Y/Y Change
Operating Cash Flow	$-47.6M	↓ 75.08%
Investing Cash Flow	$-140.8M	↑ 1327.84%
Financing Cash Flow	$100.3M	↓ 81.05%

	FY22	Y/Y Change
Operating Cash Flow	$1.7B	↓ 3595.04%
Investing Cash Flow	$-1.2B	↑ 747.54%
Financing Cash Flow	$34.8M	↓ 65.35%

	FY23	Y/Y Change
Operating Cash Flow	$-778.8M	↓ 146.82%
Investing Cash Flow	$164.6M	↓ 113.79%
Financing Cash Flow	$7.5M	↓ 78.48%

	FY24	Y/Y Change
Operating Cash Flow	$-446.4M	↓ 42.69%
Investing Cash Flow	$499.4M	↑ 203.33%
Financing Cash Flow	$4.4M	↓ 41.34%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-109.4M	↑ 1.36%
Investing Cash Flow	$28.4M	↓ 127.12%
Financing Cash Flow	$152.0K	↓ 90.95%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-77.8M	↓ 28.84%
Investing Cash Flow	$211.6M	↑ 644.57%
Financing Cash Flow	$2.9M	↑ 1835.53%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-171.5M	↑ 120.28%
Investing Cash Flow	$118.6M	↓ 43.95%
Financing Cash Flow	$31.0K	↓ 98.95%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-87.6M	↓ 48.89%
Investing Cash Flow	$140.7M	↑ 18.66%
Financing Cash Flow	$1.3M	↑ 3974.19%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-78.1M	↓ 10.86%
Investing Cash Flow	$126.8M	↓ 9.89%
Financing Cash Flow	$598.0K	↓ 52.65%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-120.2M	↑ 53.9%
Investing Cash Flow	$56.5M	↓ 55.48%
Financing Cash Flow	$2.0M	↑ 242.14%

Vir Biotechnology Technicals Summary

Sell

Neutral

Buy

Vir Biotechnology is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Vir Biotechnology Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Vir Biotechnology Inc	-1.69%	-37.56%	-36.44%	-79.68%	-85.41%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Vir Biotechnology Inc	6.4	NA	NA	-3.26	-0.46	-0.25	NA	6.82
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Vir Biotechnology Inc	Buy	$726.5M	-85.41%	6.4	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Vir Biotechnology Inc

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Organization	Vir Biotechnology
Employees	408
CEO	Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Industry	Commercial Services

Key Management of Vir Biotechnology Inc

Name	Title
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.	CEO & Director
Mr. Jason O'Byrne M.B.A.	Executive VP & CFO
Ms. Vanina de Verneuil J.D.	Executive VP, General Counsel & Corporate Secretary
Dr. Mark D. Eisner M.D., M.P.H.	Executive VP & Chief Medical Officer
Dr. Lawrence Corey M.D.	Co-Founder & Scientific Advisor
Dr. Louis J. Picker M.D.	Co-Founder & Scientific Advisor
Mr. Brent Sabatini	Senior VP, Principal Accounting Officer & Chief Accounting Officer
Dr. Maninder Hora Ph.D.	Executive VP & Chief Technical Operations Officer
Dr. Jennifer Eileen Towne Ph.D.	Executive VP & Chief Scientific Officer
Mr. Toby Medaris	Senior Vice President of Human Resources

Important FAQs about investing in VIR Stock from India :

What is Vir Biotechnology share price today?

Vir Biotechnology share price today is $4.95 as on August 30, 2025 at 1:29 am IST at the close of the market. Vir Biotechnology share today touched a day high of $5.08 and a low of $4.87.

What is the 52 week high and 52 week low for Vir Biotechnology share?

Vir Biotechnology share touched a 52 week high of $14.45 and a 52 week low of $4.16. Vir Biotechnology stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $4.95, lower by 65.74% versus the 52 week high.

How to invest in Vir Biotechnology Stock (VIR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Vir Biotechnology on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vir Biotechnology Shares that will get you 0.3030 shares as per Vir Biotechnology share price of $4.95 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Vir Biotechnology Stock (VIR) from India?

Indian investors can start investing in Vir Biotechnology (VIR) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Vir Biotechnology stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Vir Biotechnology share’s latest price of $4.95 as on August 30, 2025 at 1:29 am IST, you will get 2.0202 shares of Vir Biotechnology. Learn more about fractional shares .

What are the returns that Vir Biotechnology has given to Indian investors in the last 5 years?

Vir Biotechnology stock has given -85.41% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?